Literature DB >> 17431415

Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas.

Fumihiko Mitsui1, Yoh Dobashi, Issei Imoto, Johji Inazawa, Koji Kono, Hideki Fujii, Akishi Ooi.   

Abstract

This study was conducted to assess the frequencies of protein overexpression and gene amplification of Myc and to identify the mechanisms of Myc gene amplification, especially with regards to its possible coamplification with ERBB2 or EGFR in gastric adenocarcinomas. By immunohistochemical analysis of a total of 300 formalin-fixed and paraffin-embedded gastric adenocarcinomas, the nuclear overexpression of MYC was found in 47 tumors (16%). A fluorescence in situ hybridization (FISH) analysis revealed that nine (19%) of the 47 tumors with protein overexpression had cancer cells with high levels of Myc amplification, whereas only seven (6%) of the 122 tumors without protein overexpression showed high-level Myc gene amplification. Such Myc amplification was significantly correlated with positive nuclear protein overexpression. The coamplification of ERBB2 or EGFR with Myc that was found in six and four cases, respectively, is believed to be non-incidental because those frequencies were significantly higher than the individual frequencies observed for the total examined cases (ERBB2: 7%; EGFR: 4%). The high levels of gene amplification of these three genes, as visualized by FISH, could be broadly classified into two typical types, namely, 'multiple scattered signals' and 'large clustered signals'. Using two-color FISH, the coexistence of coamplified Myc and ERBB2, or Myc and EGFR, within single nuclei in various combinations of amplification types and copy numbers, could be ascertained in all nine cases, including one in which the synchronous 'multiple scattered type' coamplification of Myc and ERBB2 was observed. In three tumors, coamplification of ERBB2 and EGFR was found; however, ERBB2- and EGFR-amplified cell populations were separate and mutually exclusive. We propose that the non-incidental coamplification of Myc and either ERBB2 or EGFR occurred through translocation and subsequent rearrangement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431415     DOI: 10.1038/modpathol.3800777

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.

Authors:  Ahmed Basudan; Nolan Priedigkeit; Ryan J Hartmaier; Ethan S Sokol; Amir Bahreini; Rebecca J Watters; Michelle M Boisen; Rohit Bhargava; Kurt R Weiss; Maria M Karsten; Carsten Denkert; Jens-Uwe Blohmer; Jose P Leone; Ronald L Hamilton; Adam M Brufsky; Esther Elishaev; Peter C Lucas; Adrian V Lee; Steffi Oesterreich
Journal:  Mol Cancer Res       Date:  2018-10-24       Impact factor: 5.852

2.  Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.

Authors:  Akishi Ooi; Takeru Oyama; Ritsuko Nakamura; Ryosuke Tajiri; Hiroko Ikeda; Sachio Fushida; Hiroyuki Nakamura; Yoh Dobashi
Journal:  Mod Pathol       Date:  2015-03-06       Impact factor: 7.842

3.  MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.

Authors:  Federico Cappuzzo; Marileila Varella-Garcia; Elisa Rossi; Sujatha Gajapathy; Marialuisa Valente; Harry Drabkin; Robert Gemmill
Journal:  J Thorac Oncol       Date:  2009-04       Impact factor: 15.609

4.  Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.

Authors:  Joost C M Uitdehaag; Jeroen A D M de Roos; Antoon M van Doornmalen; Martine B W Prinsen; Jill A P Spijkers-Hagelstein; Judith R F de Vetter; Jos de Man; Rogier C Buijsman; Guido J R Zaman
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

5.  CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.

Authors:  Li-Chi Huang; Ka-Wai Tam; Wei-Ni Liu; Chun-Yu Lin; Kai-Wen Hsu; Wen-Shyang Hsieh; Wei-Ming Chi; Ai-Wei Lee; Jinn-Moon Yang; Ching-Ling Lin; Chia-Hwa Lee
Journal:  Dis Markers       Date:  2018-04-12       Impact factor: 3.434

6.  MYC amplifications are common events in childhood osteosarcoma.

Authors:  Solange De Noon; Jannat Ijaz; Tim Hh Coorens; Fernanda Amary; Hongtao Ye; Anna Strobl; Iben Lyskjaer; Adrienne M Flanagan; Sam Behjati
Journal:  J Pathol Clin Res       Date:  2021-05-09

7.  Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.

Authors:  J-S Kim; M-A Kim; T M Kim; S-H Lee; D-W Kim; S-A Im; T-Y Kim; W H Kim; H-K Yang; D S Heo; Y-J Bang; K-U Lee; K-J Choe; N K Kim
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

8.  Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysis.

Authors:  Ti-Chun Chan; Yi-Ting Chen; Kien Thiam Tan; Chia-Ling Wu; Wen-Jeng Wu; Wei-Ming Li; Ju-Ming Wang; Yow-Ling Shiue; Chien-Feng Li
Journal:  Clin Transl Med       Date:  2021-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.